Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Since Abcam's acquisition in 2023, founder Jonathan Milner has been making waves with his investment strategy. Discover his ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

Advanced therapy medicinal products (ATMPs) are pushing the boundaries of medicine, offering hope for previously untreatable ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

Discover six exosome therapy companies developing these tiny extracellular vesicles to treat an array of diseases.

The companies Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics bagged the biggest private biotech ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...

What’s behind the dip in investment in the gene therapy sector? As promising as gene therapies are, one of the main issues for investors is that these types of treatments come with a lot of risk and, ...